EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort

Peter Ka-Fung Chiu iD, Alex Qinyang Liu, Sui-Yan Lau, Jeremy Yuen-Chun Teoh iD, Chi-Chun Ho, Chi-Hang Yee iD, See-Ming Hou, Chi-Kwok Chan, Wai-Lun Tang, Chris H Bangma, Peggy Sau-Kwan Chu, Wing-Tat Poon und 2 weitere

BJU International · 2025

DOI: 10.1111/bju.16457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Peter Ka-Fung Chiu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To prospectively evaluate how the Prostate Health Index (PHI) impacts on clinical decision in a real‐life setting for men with a prostate‐specific antigen (PSA) level between 4 and 10 ng/mL and normal digital rectal examination. Patients and Methods Since 2016, the PHI has been available at no cost to eligible men in all Hong Kong public hospitals. All eligible patients who received PHI testing in all public Urology units ( n = 16) in Hong Kong between May 2016 and August 2017 were prospectively included and followed up. All included men had a PHI test, with its result and implications explained; the subsequent follow‐up plan was then decided via shared decision‐making with urologists. Patients were followed up for 2 years, with outcomes including prostate biopsy rates and biopsy findings analysed in relation to the initial PHI measurements.

Results

A total of 2828 patients were followed up for 2 years. The majority (82%) had PHI results in the lower risk range (score

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenHumansMaleProspective StudiesMiddle AgedAgedBiopsyProstateHong KongClinical Decision-MakingDigital Rectal ExaminationFollow-Up Studies

Stichwörter der Autor:innen

Prostate Health Index[‐2]proPSAbiomarkersdiagnosisprostate cancerprostate‐specific antigenscreening

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.
  • Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Division of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong, China.

ORCID-Profile: Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Chi-Hang Yee, Monique J Roobol

Zitieren

APA

Chiu, P. K., Liu, A. Q., Lau, S. Y., Teoh, J. Y., Ho, C. C., Yee, C. H., Hou, S. M., Chan, C. K., Tang, W. L., Bangma, C. H., Chu, P. S., Poon, W. T., Ng, C. F., & Roobol, M. J. (2025). A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU International. https://doi.org/10.1111/bju.16457

Vancouver

Chiu PK, Liu AQ, Lau SY, Teoh JY, Ho CC, Yee CH, et al. A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU International. 2025. doi:10.1111/bju.16457

BibTeX
@article{Chiu2025,
  author = {Chiu, Peter Ka-Fung and Liu, Alex Qinyang and Lau, Sui-Yan and Teoh, Jeremy Yuen-Chun and Ho, Chi-Chun and Yee, Chi-Hang and Hou, See-Ming and Chan, Chi-Kwok and Tang, Wai-Lun and Bangma, Chris H and Chu, Peggy Sau-Kwan and Poon, Wing-Tat and Ng, Chi-Fai and Roobol, Monique J},
  title = {A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16457}
}
Kostenlos starten →